Top

Published in:

01-05-2014 | Research Article

Clinical significance and biological roles of CRKL in human bladder carcinoma

Authors: Bin Han, Lan Luan, Zhenqun Xu, Bin Wu

Published in: Tumor Biology | Issue 5/2014

Abstract

CRKL encodes an adaptor protein that has been recently reported to be overexpressed in various cancers and associate with the malignant behavior of cancer cells. However, the expression pattern of CRKL protein and its clinical significance in human bladder cancer have not been well characterized to date. In the present study, CRKL expression was analyzed in 82 archived bladder cancer specimens using immunohistochemistry, and the correlations between CRKL expression and clinicopathological parameters were evaluated. We found that CRKL was overexpressed in 31 of 82 (37.8 %) bladder cancer specimens. A significant association was observed between CRKL overexpression and tumor status (p = 0.019). To further explore the biological functions of CRKL in bladder cancer, we overexpressed CRKL in BIU-87 and 5637 cell lines. Using CCK8 assay and colony formation assay, we showed that CRKL upregulation increased cell proliferation. In addition, transwell assay showed that CRKL could also facilitate invasion. Further study demonstrated that CRKL upregulation increased cyclin D1 expression and ERK phosphorylation. In conclusion, CRKL is overexpressed in bladder cancer and regulates malignant cell growth and invasion, which makes CRKL a candidate therapeutic target for bladder cancer.

Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMed

Liang PY, Li HY, Zhou ZY, Jin YX, et al. Overexpression of immunoglobulin G prompts cell proliferation and inhibits cell apoptosis in human urothelial carcinoma. Tumour Biol. 2013;34:1783–91.CrossRefPubMedPubMedCentral

Tian F, Xu F, Zhang ZY, Ge JP, et al. Expression of CHD1L in bladder cancer and its influence on prognosis and survival. Tumour Biol. 2011;34:3687–90.CrossRef

Sapre, N, Anderson PD, Costello AJ, Hovens CM, et al., Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise? Urol Oncol. 2013 Oct 17. pii: S1078-1439(13)00289-5. doi: 10.1016/j.urolonc.2013.07.002. [Epub ahead of print]

Sanchez-Carbayo M. Hypermethylation in bladder cancer: biological pathways and translational applications. Tumour Biol. 2012;33:347–61.CrossRefPubMed

Shan GY, Zhang Z, Chen QG, Yu XY, et al. Overexpression of RIN1 associates with tumor grade and progression in patients of bladder urothelial carcinoma. Tumour Biol. 2012;33:847–55.CrossRefPubMed

Atkins CD, Wrzesinski SH. Radiotherapy plus chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2010;367:380. author reply 380-1.

ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, et al. Tyrosine phosphorylation of CRKL in Philadelphia + leukemia. Blood. 1994;84:1731–6.PubMed

ten Hoeve J, Morris C, Heisterkamp N, Groffen J. Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene. 1993;8:2469–74.PubMed

10.

Feller SM. Crk family adaptors-signalling complex formation and biological roles. Oncogene. 2001;20:6348–71.CrossRefPubMed

11.

Zhao T, Miao Z, Wang Z, Xu Y, et al. Overexpression of CRKL correlates with malignant cell proliferation in breast cancer. Tumour Biol. 2013;34:2891–7.CrossRefPubMed

12.

Singer CF, Hudelist G, Lamm W, Mueller R, et al. Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep. 2006;15:353–9.PubMed

13.

Kim YH, Kwei KA, Girard L, Salari K, et al. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene. 2009;29:1421–30.CrossRefPubMedPubMedCentral

14.

Ladanyi M. CRKL as a lung cancer oncogene and mediator of acquired resistance to EGFR inhibitors: is it all that it is cracked up to be? Cancer Discov. 2011;1:560–1.CrossRefPubMedPubMedCentral

15.

Wang Y, Dong QZ, Fu L, Stoecker M, et al. Overexpression of Crkl correlates with poor prognosis and cell proliferation in non-small cell lung cancer. Mol Carcinog. 2011;52:890–9.CrossRef

16.

Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 2007;98:629–35.CrossRefPubMed

17.

Witzel II, Koh LF, Perkins ND. Regulation of cyclin D1 gene expression. Biochem Soc Trans. 2010;38:217–22.CrossRefPubMed

18.

Fristrup N, Birkenkamp-Demtroder K, Reinert T, Sanchez-Carbayo M, et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol. 2013;182:339–49.CrossRefPubMed

19.

Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4:937–47.CrossRefPubMed

20.

Webb CP, Van Aelst L, Wigler MH, Vande Woude GF. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci U S A. 1998;95:8773–8.CrossRefPubMedPubMedCentral

21.

Arai A, Aoki M, Weihua Y, Jin A, et al. CrkL plays a role in SDF-1-induced activation of the Raf-1/MEK/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells. Cell Signal. 2006;18:2162–71.CrossRefPubMed

22.

Xu YY, Mao XY, Song YX, Zhao F, et al. Midkine confers adriamycin resistance in human gastric cancer cells. Tumour Biol. 2012;33:1543–8.CrossRefPubMed

23.

Hu L, Xia L, Zhou H, Wu B, et al. TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCalpha and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620. Tumour Biol. 2002;34:2573–81.CrossRef

24.

Lee EJ, Lee SJ, Kim S, Cho SC, et al. Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-kappaB/AP-1 pathway: involvement of the p21WAF1 expression. Cell Signal. 2013;25:2025–38.CrossRefPubMed

25.

Yang C, Klein EA, Assoian RK, Kazanietz MG. Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1. Biochem J. 2008;410:167–75.CrossRefPubMed

26.

Dong QZ, Wang Y, Tang ZP, Fu L, et al. Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. Am J Pathol. 2013;182:954–64.CrossRefPubMed

Title: Clinical significance and biological roles of CRKL in human bladder carcinoma
Authors: Bin Han
Lan Luan
Zhenqun Xu
Bin Wu
Publication date: 01-05-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1536-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

Association study of SNPs of genes IFNGR1 (rs137854905), GSTT1 (rs71748309), and GSTP1 (rs1695) in gastric cancer development in samples of patient in the northern and northeastern Brazil

An analysis of the most-cited research papers on oncology: which journals have they been published in?

A cancer-related protein 14-3-3ζ is a potential tumor-associated antigen in immunodiagnosis of hepatocellular carcinoma

Upregulation of SCC-S2 in immune cells and tumor tissues of papillary thyroid carcinoma

VEGF +405G/C (rs2010963) polymorphisms and digestive system cancer risk: a meta-analysis

Relationship of serum levels of VEGF and TGF-β1 with radiosensitivity of elderly patients with unresectable non-small cell lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer